JP2011500506A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011500506A5 JP2011500506A5 JP2009548186A JP2009548186A JP2011500506A5 JP 2011500506 A5 JP2011500506 A5 JP 2011500506A5 JP 2009548186 A JP2009548186 A JP 2009548186A JP 2009548186 A JP2009548186 A JP 2009548186A JP 2011500506 A5 JP2011500506 A5 JP 2011500506A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- nervous system
- day
- term
- oxygen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 11
- 229910052760 oxygen Inorganic materials 0.000 claims 9
- 239000001301 oxygen Substances 0.000 claims 9
- 229910052717 sulfur Inorganic materials 0.000 claims 9
- 210000003169 central nervous system Anatomy 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 210000001428 peripheral nervous system Anatomy 0.000 claims 8
- 102100038238 Aromatic-L-amino-acid decarboxylase Human genes 0.000 claims 6
- 101710151768 Aromatic-L-amino-acid decarboxylase Proteins 0.000 claims 6
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 6
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 6
- 208000016285 Movement disease Diseases 0.000 claims 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 125000003435 aroyl group Chemical group 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 6
- 125000001589 carboacyl group Chemical group 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 239000011593 sulfur Substances 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 3
- 208000027534 Emotional disease Diseases 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 125000001931 aliphatic group Chemical group 0.000 claims 3
- 125000003282 alkyl amino group Chemical group 0.000 claims 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 3
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 3
- 125000004104 aryloxy group Chemical group 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 3
- 229910052794 bromium Inorganic materials 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 229910052801 chlorine Inorganic materials 0.000 claims 3
- 239000000460 chlorine Chemical group 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 239000011737 fluorine Substances 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 125000001188 haloalkyl group Chemical group 0.000 claims 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 239000011630 iodine Chemical group 0.000 claims 3
- 229910052740 iodine Chemical group 0.000 claims 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 125000001624 naphthyl group Chemical group 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 230000004962 physiological condition Effects 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical group [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 230000000698 schizophrenic effect Effects 0.000 claims 3
- 125000003107 substituted aryl group Chemical group 0.000 claims 3
- 125000004434 sulfur atom Chemical group 0.000 claims 3
- 125000004001 thioalkyl group Chemical group 0.000 claims 3
- 125000005000 thioaryl group Chemical group 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- YHKWFDPEASWKFQ-UHFFFAOYSA-N 3-nitrobenzene-1,2-diol Chemical compound OC1=CC=CC([N+]([O-])=O)=C1O YHKWFDPEASWKFQ-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07002091 | 2007-01-31 | ||
| EP07002091.2 | 2007-01-31 | ||
| PCT/PT2007/000043 WO2008094053A1 (en) | 2007-01-31 | 2007-10-10 | Dosage regimen for comt inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011500506A JP2011500506A (ja) | 2011-01-06 |
| JP2011500506A5 true JP2011500506A5 (enExample) | 2011-06-02 |
| JP5517629B2 JP5517629B2 (ja) | 2014-06-11 |
Family
ID=38961862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009548186A Active JP5517629B2 (ja) | 2007-01-31 | 2007-10-10 | Ｃｏｍｔ阻害剤用の投薬計画 |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US8524746B2 (enExample) |
| EP (2) | EP2481410B1 (enExample) |
| JP (1) | JP5517629B2 (enExample) |
| KR (1) | KR101522157B1 (enExample) |
| CN (1) | CN101631548B (enExample) |
| AR (2) | AR065098A1 (enExample) |
| AU (1) | AU2007346018A1 (enExample) |
| BR (1) | BRPI0721213B1 (enExample) |
| CA (1) | CA2678391C (enExample) |
| CY (1) | CY1118311T1 (enExample) |
| DK (2) | DK2481410T3 (enExample) |
| ES (2) | ES2597705T3 (enExample) |
| HR (1) | HRP20161261T8 (enExample) |
| HU (1) | HUE031317T2 (enExample) |
| IL (1) | IL200020A (enExample) |
| LT (1) | LT2481410T (enExample) |
| MX (1) | MX2009008051A (enExample) |
| NO (1) | NO20092905L (enExample) |
| PL (1) | PL2481410T3 (enExample) |
| PT (2) | PT2481410T (enExample) |
| RU (1) | RU2518483C2 (enExample) |
| SI (1) | SI2481410T1 (enExample) |
| WO (1) | WO2008094053A1 (enExample) |
| ZA (1) | ZA200905940B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL169855A (en) * | 2005-07-25 | 2014-05-28 | Elta Systems Ltd | A system and method for locating a receiver location |
| WO2007013830A1 (en) | 2005-07-26 | 2007-02-01 | Portela & Ca. S.A. | Nitrocatechol derivatives as comt inhibitors |
| EP1845097A1 (en) * | 2006-04-10 | 2007-10-17 | Portela & Ca., S.A. | Oxadiazole derivatives as COMT inhibitors |
| RU2009127095A (ru) | 2006-12-15 | 2011-01-20 | Эбботт Лэборетриз (Us) | Новые оксадиазольные соединения |
| DK2481410T3 (en) | 2007-01-31 | 2016-10-24 | Bial - Portela & Ca S A | Nitrocatecholderivater as COMT inhibitors administered in a specific dosage regimen |
| EP2259777A2 (en) * | 2008-02-28 | 2010-12-15 | BIAL - Portela & Ca., S.A. | Pharmaceutical composition for poorly soluble drugs |
| BRPI0908731A2 (pt) * | 2008-03-17 | 2017-05-16 | Bial - Portela & C A S A | formas cristalinas de 5-[3-(2,5-dicloro-4,6-dimetil-1-óxi-piridina-3-il)[1,2,4]oxadiazol-5-il]-3-nitrobenzeno-1,2-diol |
| BRPI0913913A2 (pt) * | 2008-07-29 | 2015-10-13 | Bial Portela & Ca Sa | regime de dosagem para nitrocatecóis |
| CN102448444B (zh) * | 2009-04-01 | 2016-05-25 | 巴尔-波特拉及康邦亚股份有限公司 | 包括硝基儿茶酚衍生物的药物制剂及其制备方法 |
| PT2413913T (pt) * | 2009-04-01 | 2022-06-09 | Bial Portela & Ca Sa | Formulações farmacêuticas que compreendem derivados de nitrocatecol e métodos para os preparar |
| WO2011069075A2 (en) * | 2009-12-04 | 2011-06-09 | Grant Jon E | Treating impulse control disorders with catechol-o- methyl-transferase inhibitors |
| US20140045900A1 (en) * | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
| US9126988B2 (en) * | 2011-12-13 | 2015-09-08 | Bial—Portela & Ca, S.A. | Intermediate for preparing a catechol-O-methyltransferase inhibitor |
| WO2016083863A1 (en) | 2014-11-28 | 2016-06-02 | Bial - Portela & Ca, S.A. | Medicaments for slowing parkinson's disease |
| CA2975401A1 (en) | 2015-01-30 | 2016-08-04 | Lieber Institute For Brain Development | Comt inhibiting methods and compositions |
| JP6858712B2 (ja) | 2015-01-30 | 2021-04-14 | リーバー インスティテュート フォー ブレイン ディベロップメントＬｉｅｂｅｒ Ｉｎｓｔｉｔｕｔｅ Ｆｏｒ Ｂｒａｉｎ Ｄｅｖｅｌｏｐｍｅｎｔ | Ｃｏｍｔ阻害方法及び組成物 |
| WO2017091818A1 (en) | 2015-11-25 | 2017-06-01 | Lieber Institute For Brain Development | Comt inhibiting methods and compositions |
| CA3078652A1 (en) | 2017-10-12 | 2019-04-18 | Novo Nordisk A/S | Semaglutide in medical therapy |
| WO2020072884A1 (en) | 2018-10-05 | 2020-04-09 | Neurocrine Biosciences, Inc. | Methods for the administration of comt inhibitors |
| EP3860603A1 (en) | 2018-10-05 | 2021-08-11 | Neurocrine Biosciences, Inc. | Methods for the administration of comt inhibitors |
| USD912395S1 (en) * | 2019-11-01 | 2021-03-09 | Jondarius Brown | Apparatus for storing earphones |
| GB202204798D0 (en) | 2022-04-01 | 2022-05-18 | Bial Portela & Ca Sa | Prodrugs of opicapone |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US660753A (en) * | 1899-11-27 | 1900-10-30 | Ferdinand-Christoph Von Heydebrand Und Der Lasa | Artificial fuel. |
| US1532178A (en) * | 1921-07-25 | 1925-04-07 | Louis A Godbold | Lubricator |
| FR1260080A (fr) | 1960-03-22 | 1961-05-05 | Materiel De Forage Soc De Fab | Trépan à molettes étanche |
| IL31990A (en) * | 1968-04-26 | 1974-05-16 | Chinoin Gyogyszer Es Vegyeszet | Pyridyl 1,2,4-oxadiazole derivatives,process for the preparation thereof and pharmaceutical compositions containing same |
| US4022901A (en) * | 1975-03-05 | 1977-05-10 | E. R. Squibb & Sons, Inc. | 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles |
| US4264573A (en) | 1979-05-21 | 1981-04-28 | Rowell Laboratories, Inc. | Pharmaceutical formulation for slow release via controlled surface erosion |
| US4386668A (en) * | 1980-09-19 | 1983-06-07 | Hughes Tool Company | Sealed lubricated and air cooled rock bit bearing |
| US5236952A (en) * | 1986-03-11 | 1993-08-17 | Hoffmann-La Roche Inc. | Catechol derivatives |
| DK175069B1 (da) | 1986-03-11 | 2004-05-24 | Hoffmann La Roche | Pyrocatecholderivater |
| YU213587A (en) | 1986-11-28 | 1989-06-30 | Orion Yhtymae Oy | Process for obtaining new pharmacologic active cateholic derivatives |
| DE3840954A1 (de) | 1988-12-05 | 1990-06-07 | Shell Int Research | Herstellung von 2-chlornicotinsaeureestern |
| EP0462639A1 (en) | 1990-06-05 | 1991-12-27 | Shell Internationale Researchmaatschappij B.V. | Preparation of 2-chloropyridine derivatives |
| DE69013689T2 (de) | 1990-11-29 | 1995-03-02 | Wei Ming Pharmaceutical Mfg Co | Hilfsträger für direkte Verpressung. |
| CA2126976A1 (en) | 1991-12-31 | 1993-07-08 | Hisashi Takasugi | Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity |
| GB9419274D0 (en) * | 1994-09-23 | 1994-11-09 | Orion Yhtymae Oy | New method for the preparation of 3,4-dihydroxy-5-nitrobenzaldehyde |
| DE19628617A1 (de) | 1996-07-16 | 1998-01-22 | Basf Ag | Direkttablettierhilfsmittel |
| US6206110B1 (en) * | 1996-09-09 | 2001-03-27 | Smith International, Inc. | Protected lubricant reservoir with pressure control for sealed bearing earth boring drill bit |
| AU762245B2 (en) * | 1998-09-18 | 2003-06-19 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
| GB2344819A (en) * | 1998-12-18 | 2000-06-21 | Portela & Ca Sa | 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones |
| FI109453B (fi) | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
| US6660753B2 (en) * | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| ATE307129T1 (de) | 1999-08-19 | 2005-11-15 | Nps Pharma Inc | Heteropolycyclische verbindungen und ihre verwendung als antagonisten von metabotropen glutamatrezeptoren |
| FI20000635A0 (fi) | 2000-03-17 | 2000-03-17 | Orion Yhtymae Oyj | COMT-inhibiittoreiden käyttö analgeettina |
| SE0001438D0 (sv) | 2000-04-18 | 2000-04-18 | Axon Chemicals Bv | New chemical compounds and their use in therapy |
| DE10029201A1 (de) | 2000-06-19 | 2001-12-20 | Basf Ag | Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstoffreisetzung |
| GB2363792A (en) | 2000-06-21 | 2002-01-09 | Portela & Ca Sa | Nitrocatechols |
| US6966488B2 (en) | 2000-08-24 | 2005-11-22 | Sagawa Express Co., Ltd. | Card payment method for service charge concerning to physical distribution or transportation |
| CN1166626C (zh) | 2000-08-30 | 2004-09-15 | 李凌松 | 三或四取代苯基化合物、其制备方法及应用 |
| WO2002044209A2 (en) | 2000-11-28 | 2002-06-06 | Zymogenetics, Inc. | Cytonkine receptor zcytor19 |
| WO2002051442A1 (en) | 2000-12-26 | 2002-07-04 | Takeda Chemical Industries, Ltd. | Concomitant drugs |
| US20040097555A1 (en) * | 2000-12-26 | 2004-05-20 | Shinegori Ohkawa | Concomitant drugs |
| PL369598A1 (en) | 2001-02-21 | 2005-05-02 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| US20030208067A1 (en) | 2001-05-30 | 2003-11-06 | Cao Sheldon Xiaodong | Inhibitors of protein kinase for the treatment of disease |
| US7041685B2 (en) * | 2001-06-08 | 2006-05-09 | Cytovia, Inc. | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| ATE352302T1 (de) | 2001-07-26 | 2007-02-15 | Merck Patent Gmbh | Verwendung von 2- 5-(4-fluorphenyl)-3- pyridylmethylaminomethyl-chroman und seiner physiologisch annehmbaren salze |
| JP4379853B2 (ja) | 2001-10-05 | 2009-12-09 | 惠民製藥股▲分▼有限公司 | 直接錠剤化用調合物および補助剤の調合方法 |
| JP2006516250A (ja) * | 2002-12-18 | 2006-06-29 | サイトビア インコーポレイティッド | カスパーゼ活性化剤およびアポトーシス誘導物質としての３，５−二置換−［１，２，４］−オキサジアゾールおよびそれらの誘導体ならびにそれらの使用 |
| WO2005006945A2 (en) * | 2003-07-03 | 2005-01-27 | The Salk Institute For Biological Studies | Methods for treating neural disorders and compounds useful therefor |
| ATE455546T1 (de) | 2003-08-06 | 2010-02-15 | Vertex Pharma | Aminotriazol-verbindungen als proteinkinase- hemmer |
| DE10338174A1 (de) | 2003-08-20 | 2005-03-24 | Lts Lohmann Therapie-Systeme Ag | Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit |
| US7300406B2 (en) | 2003-09-30 | 2007-11-27 | Carter Vandette B | Medical examination apparatus |
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| EP1751133B1 (en) | 2004-04-28 | 2010-04-14 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of rock and other protein kinases |
| GB0510143D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
| US20060173074A1 (en) | 2004-11-10 | 2006-08-03 | Juha Ellmen | Treatment of restless legs syndrome |
| EP1827453A1 (en) | 2004-12-06 | 2007-09-05 | Themis Laboratories Private Limited | Sulfonylurea compositions and a process for its preparation |
| EP1833804A1 (en) | 2004-12-28 | 2007-09-19 | AstraZeneca AB | Aryl sulphonamide modulators |
| US20080051441A1 (en) * | 2004-12-28 | 2008-02-28 | Astrazeneca Ab | Aryl Sulphonamide Modulators |
| CA2606087A1 (en) * | 2005-04-26 | 2006-11-02 | Neurosearch A/S | Novel oxadiazole derivatives and their medical use |
| US20060257473A1 (en) | 2005-05-11 | 2006-11-16 | Porranee Puranajoti | Extended release tablet |
| GB0510139D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| ES2371774T3 (es) * | 2005-06-03 | 2012-01-10 | Abbott Laboratories | Derivados de ciclobutilamina. |
| JP2007024970A (ja) | 2005-07-12 | 2007-02-01 | Miyakawa:Kk | 液晶表示装置の開口効率を上昇させるための樹脂レンズ製造法及びその製造装置 |
| US20090000437A1 (en) | 2005-07-14 | 2009-01-01 | Provo Craft And Novelty, Inc. | Methods for Cutting |
| WO2007013830A1 (en) | 2005-07-26 | 2007-02-01 | Portela & Ca. S.A. | Nitrocatechol derivatives as comt inhibitors |
| GB0515327D0 (en) * | 2005-07-26 | 2005-08-31 | Portela & Ca Sa | Comt inhibitors |
| FR2889525A1 (fr) * | 2005-08-04 | 2007-02-09 | Palumed Sa | Nouveaux derives de polyquinoleines et leur utilisation therapeutique. |
| US20070048384A1 (en) * | 2005-08-26 | 2007-03-01 | Joerg Rosenberg | Pharmaceutical compositions |
| US20090111778A1 (en) * | 2005-11-18 | 2009-04-30 | Richard Apodaca | 2-Keto-Oxazoles as Modulators of Fatty Acid Amide Hydrolase |
| US8022075B2 (en) * | 2005-11-30 | 2011-09-20 | Fujifilm Ri Pharma Co., Ltd. | Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition |
| GB0606774D0 (en) | 2006-04-03 | 2006-05-10 | Novartis Ag | Organic compounds |
| EP1845097A1 (en) | 2006-04-10 | 2007-10-17 | Portela & Ca., S.A. | Oxadiazole derivatives as COMT inhibitors |
| PE20080906A1 (es) | 2006-08-17 | 2008-07-05 | Kemia Inc | Derivados heteroarilo como inhibidores de citocina |
| US8486979B2 (en) * | 2006-12-12 | 2013-07-16 | Abbvie Inc. | 1,2,4 oxadiazole compounds and methods of use thereof |
| US20080167286A1 (en) * | 2006-12-12 | 2008-07-10 | Abbott Laboratories | Pharmaceutical compositions and their methods of use |
| DK2481410T3 (en) | 2007-01-31 | 2016-10-24 | Bial - Portela & Ca S A | Nitrocatecholderivater as COMT inhibitors administered in a specific dosage regimen |
| US8222243B2 (en) | 2007-08-27 | 2012-07-17 | Dart Neuroscience (Cayman) Ltd | Therapeutic isoxazole compounds |
| EP2259777A2 (en) * | 2008-02-28 | 2010-12-15 | BIAL - Portela & Ca., S.A. | Pharmaceutical composition for poorly soluble drugs |
| BRPI0908731A2 (pt) | 2008-03-17 | 2017-05-16 | Bial - Portela & C A S A | formas cristalinas de 5-[3-(2,5-dicloro-4,6-dimetil-1-óxi-piridina-3-il)[1,2,4]oxadiazol-5-il]-3-nitrobenzeno-1,2-diol |
| BRPI0913913A2 (pt) | 2008-07-29 | 2015-10-13 | Bial Portela & Ca Sa | regime de dosagem para nitrocatecóis |
| CN102448444B (zh) | 2009-04-01 | 2016-05-25 | 巴尔-波特拉及康邦亚股份有限公司 | 包括硝基儿茶酚衍生物的药物制剂及其制备方法 |
| PT2413913T (pt) | 2009-04-01 | 2022-06-09 | Bial Portela & Ca Sa | Formulações farmacêuticas que compreendem derivados de nitrocatecol e métodos para os preparar |
| JP5774610B2 (ja) | 2010-03-04 | 2015-09-09 | オリオン コーポレーション | パーキンソン病の治療方法 |
| US20140045900A1 (en) | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
| US9126988B2 (en) | 2011-12-13 | 2015-09-08 | Bial—Portela & Ca, S.A. | Intermediate for preparing a catechol-O-methyltransferase inhibitor |
-
2007
- 2007-10-10 DK DK12163797.9T patent/DK2481410T3/en active
- 2007-10-10 US US12/524,848 patent/US8524746B2/en active Active
- 2007-10-10 DK DK07834911.5T patent/DK2124947T3/da active
- 2007-10-10 AU AU2007346018A patent/AU2007346018A1/en not_active Abandoned
- 2007-10-10 ES ES12163797.9T patent/ES2597705T3/es active Active
- 2007-10-10 SI SI200731839A patent/SI2481410T1/sl unknown
- 2007-10-10 BR BRPI0721213-5A patent/BRPI0721213B1/pt active IP Right Grant
- 2007-10-10 WO PCT/PT2007/000043 patent/WO2008094053A1/en not_active Ceased
- 2007-10-10 PL PL12163797T patent/PL2481410T3/pl unknown
- 2007-10-10 HU HUE12163797A patent/HUE031317T2/hu unknown
- 2007-10-10 PT PT121637979T patent/PT2481410T/pt unknown
- 2007-10-10 CN CN200780050737.2A patent/CN101631548B/zh active Active
- 2007-10-10 PT PT78349115T patent/PT2124947T/pt unknown
- 2007-10-10 EP EP12163797.9A patent/EP2481410B1/en active Active
- 2007-10-10 ES ES07834911.5T patent/ES2644049T3/es active Active
- 2007-10-10 MX MX2009008051A patent/MX2009008051A/es active IP Right Grant
- 2007-10-10 RU RU2009132188/04A patent/RU2518483C2/ru active
- 2007-10-10 CA CA2678391A patent/CA2678391C/en active Active
- 2007-10-10 JP JP2009548186A patent/JP5517629B2/ja active Active
- 2007-10-10 LT LTEP12163797.9T patent/LT2481410T/lt unknown
- 2007-10-10 EP EP07834911.5A patent/EP2124947B1/en active Active
- 2007-10-10 KR KR1020097016752A patent/KR101522157B1/ko active Active
-
2008
- 2008-01-30 AR ARP080100382A patent/AR065098A1/es not_active Application Discontinuation
-
2009
- 2009-07-22 IL IL200020A patent/IL200020A/en active IP Right Grant
- 2009-08-27 ZA ZA200905940A patent/ZA200905940B/xx unknown
- 2009-08-28 NO NO20092905A patent/NO20092905L/no not_active Application Discontinuation
-
2013
- 2013-07-25 US US13/950,661 patent/US20130331416A1/en not_active Abandoned
-
2015
- 2015-04-17 US US14/689,397 patent/US9745290B2/en active Active
-
2016
- 2016-10-03 HR HRP20161261TT patent/HRP20161261T8/hr unknown
- 2016-10-12 CY CY20161101012T patent/CY1118311T1/el unknown
-
2017
- 2017-09-08 AR ARP170102484A patent/AR109590A2/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2009132188A (ru) | Режим дозирования ингибиторов комт | |
| RU2013139414A (ru) | Режим введения для нитрокатехолов | |
| RU2010154173A (ru) | Режим введения нитрокатехолов | |
| JP2012092149A5 (enExample) | ||
| US20090264443A1 (en) | Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds | |
| JP2016185995A5 (enExample) | ||
| HRP20120323T4 (hr) | Spoj diaril-hidantoina | |
| MX344308B (es) | Derivados de quinolina carboxamida y quinolina carbonitrilo como moduladores alostericos negativos de mglur2, composiciones y su uso. | |
| CY1111159T1 (el) | Πυκνα διαλυματα μεθοτρεξατης | |
| RU2010107284A (ru) | Производные нафтиридина в качестве модуляторов калиевых каналов | |
| EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
| EA200870183A1 (ru) | Долговременное лечение вич-инфекции | |
| JP2016525104A5 (enExample) | ||
| JP2019520344A5 (enExample) | ||
| JP2014512355A5 (enExample) | ||
| JP2022508513A5 (enExample) | ||
| JOP20240217A1 (ar) | مشتقات الكوينولين كمُعدِّلات للعضو x2 لمستقبل بروتين g مرتبط بـ mas ومنتجات ذات صلة | |
| EP2670405B1 (en) | Combinations comprising macitentan for the treatment of glioblastoma multiforme | |
| Kean et al. | Geriatric drug delivery―barriers, current technologies and the road ahead | |
| UA92327C2 (ru) | Применение n-арилдиазаспироциклических соединений для лечения зависимостей | |
| RU2012108144A (ru) | Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами | |
| RU2008112181A (ru) | Применение конденсированных производных имидазола для лечения заболеваний, опосредованных рецептором ccr3 | |
| RU2016110546A (ru) | Комбинированная лекарственная терапия | |
| JP2016535099A5 (enExample) | ||
| RU2012106827A (ru) | Применение производных 5н-дибенз/в, f/азепин-5-карбоксамида для лечения фибромиалгии |